We are a statewide network of professionals dedicated to the advancement of cardiovascular and pulmonary rehabilitation.

• Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline
• New Phase III Study with Nintedanib currently enrolling patients with Systemic Sclerosis and Lung Fibrosis
• Preliminary Study of Triciribine Shows Treatment and Possible Reversal of Pulmonary Fibrosis and Pulmonary Hypertension in Mice
  • Study published in British Journal of Pharmacology
• New Drug Approved May 2015 for the Maintenance of COPD: Stiolto Respimat
• Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease
• Plasma Fibrinogen Approved as a Biomarker for COPD
  • Study Showing Value of Plasma Fibrinogen as a Biomarker for COPD
• Randomized, Double-Blind Study Demonstrates Effectiveness of Augmentation Therapy to Treat Severe α1 Antitrypsin Deficiency